Brief: Novo And Hengrui Pharma Enter Exclusive License Agreement For HRS-1596

Novo Nordisk A/S

29/09/2026 05:43

Sept 29 (Reuters) - Novo Nordisk A/S NOVOb.CO:
NOVO AND HENGRUI PHARMA ENTER EXCLUSIVE LICENSE AGREEMENT FOR ONCE-WEEKLY ORAL GLP-1/GIP DUAL RECEPTOR AGONIST HRS-1596
NOVO NORDISK - DEAL VALUE UP TO $2.60 BILLION INCLUDING $300 MILLION UPFRONT AND SALES ROYALTIES
NOVO NORDISK - OBTAINS EXCLUSIVE GLOBAL RIGHTS TO HRS-1596 EXCLUDING CHINA, HONG KONG, MACAO, TAIWAN
NOVO NORDISK - HENGRUI PHARMA APPROVED TO INITIATE PHASE 1 TRIALS WITH HRS-1596 IN CHINA
NOVO AND HENGRUI PHARMA ENTER EXCLUSIVE LICENSE AGREEMENT FOR ONCE-WEEKLY ORAL GLP-1/GIP DUAL RECEPTOR AGONIST HRS-1596
Source text: ID:nGNE9XCnQQ
Further company coverage: [NOVOb.CO]

 ((Reuters.briefs@thomsonreuters.com;))